{
    "clinical_study": {
        "@rank": "104249", 
        "arm_group": [
            {
                "arm_group_label": "PharmaNAC 1800 mg", 
                "arm_group_type": "Experimental", 
                "description": "PharmaNAC 900 mg orally twice daily for 8 weeks"
            }, 
            {
                "arm_group_label": "PharmaNAC 3600 mg", 
                "arm_group_type": "Experimental", 
                "description": "PharmaNAC 1800 mg orally twice daily for 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo pills given twice daily for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to determine if n-acetylcysteine, given as PharmaNAC, reduces\n      oxidative stress and improves vascular function in HIV-infected older adults already on HIV\n      treatment."
        }, 
        "brief_title": "N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV", 
            "Endothelial Dysfunction", 
            "Oxidative Stress"
        ], 
        "detailed_description": {
            "textblock": "The primary objective of this study is to compare 8-week changes in circulating levels of\n      malondialdehyde (MDA), circulating levels of F2-isoprostanes, and flow-mediated dilation\n      (FMD) of the brachial artery in older HIV-infected adults already receiving virologically\n      suppressive antiretroviral therapy (ART) who are then randomized to either NAC 900 mg twice\n      daily, NAC 1800 mg twice daily, or placebo. The relative efficacy and safety of these two\n      doses of NAC will be assessed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or\n             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and\n             confirmed by a licensed Western blot or a second antibody test by a method other than\n             the initial rapid HIV and/or E/CIA, or (2) by two detectable HIV-1 antigens, or (3)\n             two detectable plasma HIV-1 RNA viral loads.\n\n          -  Age equal to or greater than 50 years.\n\n          -  Receipt of antiretroviral therapy of any kind for at least 6 months prior to\n             screening.\n\n          -  HIV-1 RNA level < 75 copies/mL at screening.\n\n          -  For women who are still of reproductive potential, a negative urine pregnancy test at\n             screening and willingness to use two forms of birth control during the course of the\n             study. Acceptable forms of birth control include condoms (with or without a gel that\n             can kill sperm), a diaphragm or cervical cap (with or without a gel that can kill\n             sperm), an intrauterine device (IUD), or hormonal-based birth control (\"the pill\").\n\n        Exclusion Criteria:\n\n          -  Inability to complete written, informed consent.\n\n          -  Incarceration at the time of any study visit.\n\n          -  Known allergy or intolerance to n-acetylcysteine.\n\n          -  Use of n-acetylcysteine within 180 days of screening.\n\n          -  Diagnosed vascular disease (history of angina pectoris, coronary disease, peripheral\n             vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known\n             atherosclerotic disease).\n\n          -  History of congestive heart failure even if currently compensated.\n\n          -  History of portal hypertension or hepatic cirrhosis (either clinically diagnosed or\n             histologically diagnosed).\n\n          -  Diagnosed disease or process, besides HIV infection, associated with increased\n             systemic inflammation (including, but not limited to, systemic lupus erythematosis,\n             inflammatory bowel diseases, other collagen vascular diseases).\n\n          -  Known or suspected malignancy requiring systemic treatment within six months of\n             screening.\n\n          -  History of ADA-defined diabetes mellitus (115)\n\n          -  History of migraine headaches.\n\n          -  History of Raynaud's phenomenon.\n\n          -  History of cardiac arrhythmias or cardiomyopathy.\n\n          -  Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the\n             local reference range on most recent clinical assessment.\n\n          -  Asthma or COPD requiring daily use of beta-2-agonist therapy (e.g. albuterol)\n\n          -  History of carotid bruits.\n\n          -  Creatinine clearance < 50 mL/min (using the Cockcroft-Gault equation) using a serum\n             creatinine level measured at screening.\n\n          -  Hemoglobin < 9.0 g/dL at screening.\n\n          -  Alanine aminotransferase (ALT) level or aspartate aminotransferase (AST) > 3 times\n             ULN at screening.\n\n          -  Total bilirubin > 2.5 times ULN at screening; if the participant is receiving\n             atazanavir, then s/he would be excluded if total bilirubin is > 3.5 times ULN at\n             screening.\n\n          -  Therapy for serious medical illnesses within 14 days prior to screening.\n\n          -  Pregnancy or breastfeeding during the course of the study.\n\n          -  Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg or diastolic\n             blood pressure > 100 mmHg at screening.\n\n          -  Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids\n             (of any dose), or anabolic steroids at screening.\n\n          -  Previous receipt of stavudine or didanosine for more than 7 cumulative days.\n\n          -  Receipt of daily Vitamin C or Vitamin E supplements at screening.\n\n          -  Alcohol intake more than the equivalent of one 8 oz. of wine daily for the 7 days\n             prior to screening.\n\n          -  Active drug use or dependence that, in the opinion of the investigator, would\n             interfere with adherence to study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962961", 
            "org_study_id": "IU SRI 1306011647"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PharmaNAC 1800 mg", 
                    "PharmaNAC 3600 mg"
                ], 
                "description": "PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.\nPharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days).", 
                "intervention_name": "PharmaNAC (N-acetylcysteine)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "N-acetylcysteine", 
                    "NAC"
                ]
            }, 
            {
                "arm_group_label": [
                    "PharmaNAC 1800 mg", 
                    "Placebo"
                ], 
                "intervention_name": "Matching placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "Endothelial function", 
            "Oxidative stress", 
            "Cardiovascular disease", 
            "N-acetylcysteine"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Indiana University Health University Hospital, Indiana Clinical Research Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy", 
        "overall_contact": {
            "email": "johnpaul@iu.edu", 
            "last_name": "Paula Johnson, NP", 
            "phone": "317-278-2945"
        }, 
        "overall_official": {
            "affiliation": "Indiana University School of Medicine", 
            "last_name": "Samir K Gupta, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measure of oxidative stress", 
                "measure": "Circulating malondialdehyde levels", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Oxidative stress measure", 
                "measure": "Circulating F2-isoprostane levels", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Measure of endothelial function", 
                "measure": "Flow-mediated dilation (FMD) of the brachial artery", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962961"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Indiana University", 
            "investigator_full_name": "Samir K Gupta, MD, MS", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Safety measures of PharmaNAC given at two different doses", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "4 week and 8 weeks"
        }, 
        "source": "Indiana University", 
        "sponsors": {
            "collaborator": {
                "agency": "BioAdvantex Pharma", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}